The FDA approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals) with oxaliplatin, fluorouracil and leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma.
Efficacy was evaluated in NAPOLI 3 (ClinicalTrials.gov Identifier: NCT04083235), a randomized, multicenter, open-label, active-controlled trial in 770 patients with metastatic pancreatic adenocarcinoma who had not previously received chemotherapy in the metastatic setting. Randomization was stratified by